Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
Asterias Biotherapeutics, Inc. (AST) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/24/2019 GN Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
01/04/2019 GN BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase
11/27/2018 GN Asterias Biotherapeutics Announces Fourth Patient Dosed in First-in-Human Clinical Study of Immunotherapy VAC2 in Non-Small Cell Lung Cancer
11/02/2018 GN Asterias Biotherapeutics to Report Third Quarter 2018 Results on November 12, 2018
10/31/2018 GN Asterias Biotherapeutics Announces Positive Outcome from Data Review from OPC1 Spinal Cord Injury Study
09/20/2018 GN FDA Accepts Asterias Biotherapeutics' Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program
09/12/2018 GN Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
09/04/2018 GN Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
08/29/2018 GN Asterias Biotherapeutics' CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR Healthcare Conference
08/09/2018 GN Asterias Biotherapeutics Reports Second Quarter Financial Results and Recent Development Progress
07/31/2018 GN Asterias Provides 12 Month Cohort 3 and 4 Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
07/17/2018 GN Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
07/12/2018 GN Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AST-OPC1 for the Treatment of Stroke
07/11/2018 GN Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
06/12/2018 GN Asterias Biotherapeutics Announces First Patient Dosed in First-in-Human Clinical Study of Immunotherapy AST-VAC2 in Non-Small Cell Lung Cancer
06/05/2018 GN Asterias Biotherapeutics Announces Independent Data Monitoring Committee Completes Last Intermediate Review of AST-OPC1 Clinical Trial in Acute Spinal Cord Injury
05/09/2018 GN Asterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress
05/03/2018 GN Asterias Biotherapeutics to Report First Quarter 2018 Results on May 9, 2018
05/02/2018 GN Asterias Biotherapeutics to Present Safety and Efficacy Data from AST-OPC1 SCiStar Study at the American Spinal Injury Association (ASIA) 2018 Annual Meeting                                                                         
04/27/2018 GN Asterias Biotherapeutics to Present AST-OPC1 Program Update at the Upcoming American Society for Neural Therapy and Repair Conference
03/15/2018 GN Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Developments
03/09/2018 GN Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2017 Results on March 15, 2018
02/28/2018 GN  Asterias Provides Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
01/04/2018 GN Asterias Biotherapeutics Reports Milestone Targets for 2018
12/19/2017 GN Asterias Biotherapeutics Completes Enrollment of Entire SCiStar Study
11/16/2017 GN Asterias Biotherapeutics to Present at Piper Jaffray Healthcare Conference on November 28, 2017
11/14/2017 GN Asterias Biotherapeutics Reports Third Quarter Financial Results and Recent Developments
10/19/2017 GN Asterias Biotherapeutics Announces Closing of $10.4 Million Registered Direct Offering
10/16/2017 GN Asterias Biotherapeutics Announces $10.4 Million Registered Direct Offering
10/02/2017 GN Asterias Announces Two Significant Developments for Spinal Cord Injury Program
09/26/2017 GN Asterias Receives Regulatory Clearance to Initiate Clinical Study of AST-VAC2 in Subjects with Early and Late Stage Non-Small Cell Lung Cancer
09/25/2017 GN Asterias' AST-OPC1 Clinical Trial Will Continue as Planned Following Recommendation of Data Monitoring Committee
08/30/2017 GN Preclinical Data Published in Peer-Reviewed Journal Stem Cells Translational Medicine Provides Scientific Framework for Asterias' AST-OPC1 for the Treatment of Subacute Cervical Spinal Cord Injury
08/14/2017 GN Asterias Biotherapeutics Reports Second Quarter Financial Results and Reviews Recent Clinical Progress and Corporate Developments

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy